Optimal two-stage designs for phase II clinical trials with differentiation of complete and partial responses

Communications in Statistics - Theory and Methods

Volumn 29, Issue 5-6, 2000, Pages 923-940

  Lin, Shang P ^a   Chen, T Timothy ^b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Cancer clinical trials; Drug screening; Optimization; Phase II trials; Trinomial

Indexed keywords

EID: 0009993920     PISSN: 03610926     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Atkinson, E. N. and Brown, B. W. (1985). Confidence limits for probability of response in multistage phase II clinical trials. Biometrics, 41, 741-744.
2. Cheson, B. D., Cassileth, P. A., Head, D. A., Schiffer, C. A., Bennett, J. M., Bloomfield, C. D., Brunning R., Gale, R. P., Grever, M. R., Keating, M. J., Sawitsky, A., Stass, S., Weinstein, H., and Woods, W. G. (1990). Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J of Clinical Oncology, 8, 813-819.
3. DeVita, V. T. (1993). Principles of chemotherapy. In: DeVita, V. T., Hellman, S., and Rosenberg, S. A.,eds. Cancer: Principles and Practice of Oncology. Fourth Edition. Philadelphia, Penn: J. B. Lippincott Co., 276-292.
4. Fleming, T. R. (1982). One sample multiple testing procedure for phase II clinical trials. Biometrics, 38, 143-151.
5. Frei III, E. (1985). Curative cancer chemotherapy. Cancer Research, 45, 6523-6537.
6. Herndon, J. E. (1998). A design alternative for two-stage, phase II, multicenter cancer clinical trials. Controlled Clinical Trials, 19, 440-450.
7. O'Brien, P. C. and Fleming, T. R. (1979). A multiple testing procedure for clinical trials. Biometrics, 35, 549-556.
8. Pocock, S. J. (1977). Group sequential methods in the design and analysis of clinical trials. Biometrika, 64, 191-199.
9. Schultz, J. R., Nichol, F. R., Elfring, G. L., and Weed, S.D. (1973). Multiple-stage procedures for drug screening. Biometrics, 29, 293-300.
10. Simon, R. (1987). How large should a phase II trial be? Cancer Treatment Report, 71, 1079-1085.
11. Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials, 10, 1-10.